They have historically filed late, so why should w
Post# of 15624
(Total Views: 276)
Posted On: 08/14/2017 7:49:39 PM
They have historically filed late, so why should we expect it to be different this quarter.
I think what we all need to recognize is that this company is being run on a shoestring by a number of highly qualified people who are doing it part time. The company has tremendous experience but doesn't yet have the funding necessary to employ full time employees. What they have done is avail themselves with tremendous alliances that permitted them to develop and try drugs at very low cost to the company.
The company's close relationship with Sheba Hospital has provided them with the ability to run trials at very low costs to them. Likewise their relationship with Emilia permits them to supply product at essentially no cost to them. Of course Sheba, Emilia, etc. should earn nicely from product sales once they're established, but for now, OWCP can function with a very low burn rate and minimal company owned or leased facilities and still develop products which could sell in the seven digit or higher dollar range in a matter of years.
With the low cost operation, I believe it's perfectly acceptable and understandable that things like quarterly and annual reports are delayed to the point that they can be, but they do meet the mandatory deadlines.
While I would certainly like them to be clearer in what they say in their reports, I think it's very natural that delays that cannot be controlled by the company do occur, I've never seen a Biotech that didn't have delays in bringing product to market. While I'd love to see sales of the cream this year, if it turns out that it takes until this time next years to initiate sales, those who remain invested, and perhaps average down, will be very well served by the company.
Gary
I think what we all need to recognize is that this company is being run on a shoestring by a number of highly qualified people who are doing it part time. The company has tremendous experience but doesn't yet have the funding necessary to employ full time employees. What they have done is avail themselves with tremendous alliances that permitted them to develop and try drugs at very low cost to the company.
The company's close relationship with Sheba Hospital has provided them with the ability to run trials at very low costs to them. Likewise their relationship with Emilia permits them to supply product at essentially no cost to them. Of course Sheba, Emilia, etc. should earn nicely from product sales once they're established, but for now, OWCP can function with a very low burn rate and minimal company owned or leased facilities and still develop products which could sell in the seven digit or higher dollar range in a matter of years.
With the low cost operation, I believe it's perfectly acceptable and understandable that things like quarterly and annual reports are delayed to the point that they can be, but they do meet the mandatory deadlines.
While I would certainly like them to be clearer in what they say in their reports, I think it's very natural that delays that cannot be controlled by the company do occur, I've never seen a Biotech that didn't have delays in bringing product to market. While I'd love to see sales of the cream this year, if it turns out that it takes until this time next years to initiate sales, those who remain invested, and perhaps average down, will be very well served by the company.
Gary
(1)
(0)